logo
welcome
Reuters

Reuters

US FDA declines to approve Regeneron's blood cancer therapy

Reuters
Summary
Nutrition label

79% Informative

Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma.

FDA said sole issue identified for approval is related to findings from a pre-approval inspection at a third -party manufacturer.

Regeneron said it is committed to working closely with the third party manufacturer and the health regulator.

VR Score

88

Informative language

96

Neutral language

28

Article tone

formal

Language

English

Language complexity

80

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links